DOCSLIB.ORG
  • Sign Up
  • Log In
  • Upload
  • Sign Up
  • Log In
  • Upload
  • Home
  • »  Tags
  • »  Bezafibrate

Bezafibrate

  • Statins and Lipid Lowering Agents

    Statins and Lipid Lowering Agents

  • Clinofibrate Improved Canine Lipid Metabolism in Some but Not All Breeds

    Clinofibrate Improved Canine Lipid Metabolism in Some but Not All Breeds

  • Effects of Clofibrate Derivatives on Hyperlipidemia Induced by a Cholesterol-Free, High-Fructose Diet in Rats

    Effects of Clofibrate Derivatives on Hyperlipidemia Induced by a Cholesterol-Free, High-Fructose Diet in Rats

  • Bezalip, 200 Mg Film Coated Tablets Bezalip Retard, 400 Mg Sustained Release, Film Coated Tablets

    Bezalip, 200 Mg Film Coated Tablets Bezalip Retard, 400 Mg Sustained Release, Film Coated Tablets

  • (CPG) for the Management of Dyslipidemia for Cardiovascular

    (CPG) for the Management of Dyslipidemia for Cardiovascular

  • (12) United States Patent (10) Patent No.: US 7,795,310 B2 Lee Et Al

    (12) United States Patent (10) Patent No.: US 7,795,310 B2 Lee Et Al

  • Low Doses of Fenofibrate and Bezafibrate Stimulate Renal 2-Oxoglutarate Dehydrogenase (2-Ogdh) in Protein-Restricted Rats

    Low Doses of Fenofibrate and Bezafibrate Stimulate Renal 2-Oxoglutarate Dehydrogenase (2-Ogdh) in Protein-Restricted Rats

  • Pharmacological Targeting of the Atherogenic Dyslipidemia Complex: the Next Frontier in CVD Prevention Beyond Lowering LDL Cholesterol

    Pharmacological Targeting of the Atherogenic Dyslipidemia Complex: the Next Frontier in CVD Prevention Beyond Lowering LDL Cholesterol

  • PI Changes for Fibrates

    PI Changes for Fibrates

  • Fenofibrate, Bezafibrate, Ciprofibrate and Gemfibrozil Procedure Number

    Fenofibrate, Bezafibrate, Ciprofibrate and Gemfibrozil Procedure Number

  • Effect of Low Doses of Bezafibrate and Fenofibrate on Liver 2-Oxoglutarate

    Effect of Low Doses of Bezafibrate and Fenofibrate on Liver 2-Oxoglutarate

  • Lipid Lowering Drugs Prescription and the Risk of Peripheral Neuropathy

    Lipid Lowering Drugs Prescription and the Risk of Peripheral Neuropathy

  • Anatomical Classification Guidelines V2020 EPHMRA ANATOMICAL

    Anatomical Classification Guidelines V2020 EPHMRA ANATOMICAL

  • Treatment Strategy for Dyslipidemia in Cardiovascular Disease Prevention: Focus on Old and New Drugs

    Treatment Strategy for Dyslipidemia in Cardiovascular Disease Prevention: Focus on Old and New Drugs

  • (PPAR) Agonists Activate Hepatitis B Virus Replication in Vivo Lingyao Du, Yuanji Ma, Miao Liu, Libo Yan and Hong Tang*

    (PPAR) Agonists Activate Hepatitis B Virus Replication in Vivo Lingyao Du, Yuanji Ma, Miao Liu, Libo Yan and Hong Tang*

  • Review of Existing Classification Efforts

    Review of Existing Classification Efforts

  • Study Protocol 1002-046 Amendment 1, 10 April 2017

    Study Protocol 1002-046 Amendment 1, 10 April 2017

  • STATIN-FIBRATE REPORT: Focus on Safety VHA Pharmacy Benefits Management-Strategic Healthcare Group and the Medical Advisory Panel

    STATIN-FIBRATE REPORT: Focus on Safety VHA Pharmacy Benefits Management-Strategic Healthcare Group and the Medical Advisory Panel

Top View
  • 1. NAME of the MEDICINAL PRODUCT Fluvastatin 20 Mg / 40
  • Antidiabetic Action of Bezafibrate in a Large Observational Database
  • Development of a LC-MS/MS Method for the Estimation of Clinofibrate In
  • Newer Approaches to the Management of Pruritus in Cholestatic Liver Disease
  • PPAR Agonist Fenofibrate Suppresses Tumor Growth Through Direct
  • Elucidation of Molecular Mechanism of a Selective PPAR Modulator
  • Lipid Management in Patients with Endocrine Disorders: an Endocrine
  • Pharmaceutical Composition Comprising a Combination Of
  • Prevention of Murine Atherosclerosis with Bempedoic Acid
  • PPAR-Mediated Toxicology and Applied Pharmacology
  • Cardiovascular Diabetology Biomed Central
  • Bezalip and Bezalip Retard CMI
  • Ezetimibe for Lowering Blood Cholesterol
  • Package Leaflet: Information for the Patient Fenofibrate 200 Mg
  • The Use of Stems in the Selection of International Nonproprietary Names (INN) for Pharmaceutical Substances
  • Fibrates (Fi – Brates)
  • Bezafibrate Induced Rhabdomyolysis
  • Lipid Modification to Reduce Cardiovascular Risk


© 2024 Docslib.org    Feedback